Women with a history of cardiotoxicity from previous cancer treatments are around 30 percent more likely to experience clinical congestive heart failure (CHF) before, during or after pregnancy, according to research published ahead of print in the Journal of the American College of Cardiology.

The 17,000-member American Society of Echocardiography (ASE) named Jonathan R. Lindner, MD, president of the organization during its 29th annual scientific sessions in Nashville, Tennessee.

A deep-learning software that can automatically calculate left ventricular ejection fraction (LVEF) with less variability than a cardiologist recently received approval from the U.S. Food and Drug Administration (FDA).

ImageGuideEcho—the first registry devoted solely to measuring quality in cardiovascular ultrasounds— is now open to U.S. physicians.

As life expectancy continues to expand for cancer patients, clinicians are increasingly dealing with oncological complications like cardiotoxicity, according to a medical team in the Netherlands—and those doctors are met with a paucity of research on the topic.

Automated 3D echocardiography (3DE) analysis using a new, commercially available algorithm has allowed University of Chicago researchers to accurately quantify left-heart size and function in two-thirds of 300 consecutive patients. They conclude the technology can be useful in clinical practice despite its known workflow-interruptive drawbacks—especially when the echocardiographer has the know-how to correct for its shortcomings.

Treating today’s cancer patient no longer means simply targeting the cancer. Given the known cardiotoxicities of some established chemotherapies and the possibility that newer approaches may damage the heart, oncologists, cardiologists and imaging specialists now work together to detect and minimize the risk of treatment-induced heart failure.

ASE says new data may be a “wake-up call” to recognize the value of echocardiography.